ABCL Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -10.71%, SMA50 -17.04%, SMA200 -23.2%). The stock’s 14-day RSI is 39.08 (weak momentum), while the ATR of 0.25 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -53.34% below its high and over 60.8% above its low. Average 10-day trading volume of 2.95 million shares is below the 3-month average of 4.13 million, indicating normal recent market interest.

AbCellera Biologics Inc. generated EPS of -$0.58 over the past year. Five-year average earnings growth is -107.74%. Wall Street analysts project EPS growth of 13.99% annually over the next five years. The latest quarter delivered EPS of -$0.17. The next quarter is forecast at -$0.13. Next year's EPS is expected at -$13.97. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 2 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $4.00. The high target offers 228.95% upside. The low target suggests 31.58% downside. The mean target is $7.20. This offers 136.84% upside. AbCellera Biologics Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 0.0%. The prior quarter beat by -29.41%. Over the last six quarters, Apple has recorded several small beats. These include -13.33% in August 06, 2024.

AbCellera Biologics Inc. has 299.34 million shares outstanding. The public float is 204.33 million shares, elevated short interest at 21.19% of float. This equals 48.90 million shares. The short ratio is 10.08 days. Institutional investors hold 48.87% of the float. Insiders own 22.92%. Thermopylae Holdings Ltd. holds 56.14 million shares, THIEL PETER has 10.18 million shares and Lecault Veronique has 2.04 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

AbCellera Biologics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.84. This means the shares are trading below this model’s fair value.

AbCellera Biologics Inc. (NASDAQ:ABCL) closed at $3.04 USD, losing -$0.18 (-5.59%) from the previous close of $3.22. The stock is currently mid-range between its 52-week high and low $1.89 and $6.51. With a market capitalization of about $909.98 million, AbCellera Biologics Inc. is classified as a small-cap and shows market-like volatility (beta ~0.84). Key stats such as the average daily volume over the past year has been around 4.18 million shares, in line with its 52-week average. Headquartered in Vancouver, BC, AbCellera Biologics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Carl Hansen, the company employs approximately 596 people and listed since December 11, 2020. AbCellera Biologics Inc. develops antibody discovery platform.

AbCellera Biologics Inc. trades at a P/E ratio of -5.29, slightly below the S&P 500 average, with a price-to-sales ratio of 25.76 and a price-to-book ratio of 0.94 suggesting the stock is closer to book value. The P/FCF stands at -5.94, also above market averages.

AbCellera Biologics Inc. (NASDAQ:ABCL) shares are up 21.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows AbCellera Biologics Inc. trading at a premium to the broader market with a P/E of -5.29. Analyst sentiment is cautious, with the majority of ratings in Market Perform territory and a mean price target of $17.50, suggesting 475.66% upside. Our AI forecast model points to short-term weakness (-17.11% over two weeks), a medium-term fall (-59.54% over three months), and a longer-term gain (195.39% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that AbCellera Biologics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -17.11%, with price expected at $2.52 by March 06, 2026, within a range of $2.15 to $2.88 3-Month Outlook: Projected fall of -59.54%, reaching $1.23 by May 21, 2026, with a range of $1.09 to $1.36. 1-Year Outlook: Projected gain of 195.39%, with price at $8.98 by February 19, 2027, within a range of $1.26 to $14.56.